Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-04-06 4:50 pm Purchase |
2023-03-31 | 13G | Owens & Minor, Inc. OMI |
James E. Flynn | 4,202,667 5.510% |
4,202,667 (New Position) |
Filing History |
| 2023-03-28 09:37 am Purchase |
2023-03-27 | 13D | CalciMedica, Inc. CALC |
James E. Flynn | 377,264 6.840% |
377,264 (New Position) |
Filing History |
| 2023-03-27 4:09 pm Purchase |
2023-03-22 | 13D | Graybug Vision, Inc. GRAY |
James E. Flynn | 1,713,873 24.490% |
1,336,608 (+354.29%) |
Filing History |
| 2023-03-22 4:17 pm Purchase |
2023-03-13 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
James E. Flynn | 4,627,310 6.090% |
2,278,082 (+96.97%) |
Filing History |
| 2023-03-16 5:41 pm Purchase |
2023-03-14 | 13D | Larimar Therapeutics, Inc. LRMR |
James E. Flynn | 16,973,635 39.200% |
10,606 (+0.06%) |
Filing History |
| 2023-02-27 5:43 pm Purchase |
2023-02-17 | 13G | Galera Therapeutics, Inc. GRTX |
James E. Flynn | 2,916,401 4.990% |
2,916,401 (New Position) |
Filing History |
| 2023-02-13 5:28 pm Purchase |
2023-02-01 | 13G | Pulmonx Corporation LUNG |
James E. Flynn | 2,465,263 6.590% |
2,465,263 (New Position) |
Filing History |
| 2023-02-13 5:03 pm Sale |
2022-12-31 | 13G | Pulmonx Corporation LUNG |
James E. Flynn | 0 0.000% |
-2,366,867 (Position Closed) |
Filing History |
| 2023-02-10 3:59 pm Sale |
2022-12-31 | 13G | Phathom Pharmaceuticals, Inc. PHAT |
James E. Flynn | 0 0.000% |
-2,414,897 (Position Closed) |
Filing History |
| 2023-02-10 3:57 pm Unchanged |
2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
James E. Flynn | 2,851,287 5.760% |
0 (Unchanged) |
Filing History |
| 2023-02-10 2:32 pm Purchase |
2022-12-31 | 13G | Nuvalent, Inc. NUVL |
James E. Flynn | 25,471,666 39.250% |
4,777 (+0.02%) |
Filing History |
| 2023-02-10 2:31 pm Sale |
2022-12-31 | 13G | AdaptHealth Corp. AHCO |
James E. Flynn | 21,673,897 5.660% |
-2,598,531 (-10.71%) |
Filing History |
| 2023-02-10 2:29 pm Sale |
2022-12-31 | 13G | Singular Genomics Systems, Inc. OMIC |
James E. Flynn | 299,362 9.070% |
-5,372 (-1.76%) |
Filing History |
| 2023-02-10 2:27 pm Purchase |
2022-12-31 | 13G | Peak Bio, Inc. PKBO |
James E. Flynn | 362,500 1.780% |
362,500 (New Position) |
Filing History |
| 2023-02-10 10:11 am Unchanged |
2022-12-31 | 13G | Turmeric Acquisition Corp. TMPM |
James E. Flynn | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2023-02-10 10:10 am Unchanged |
2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
James E. Flynn | 1,324,214 4.960% |
0 (Unchanged) |
Filing History |
| 2023-02-10 10:09 am Sale |
2022-12-31 | 13G | Silk Road Medical, Inc SILK |
James E. Flynn | 1,396,640 3.660% |
-465,277 (-24.99%) |
Filing History |
| 2023-02-10 10:08 am Sale |
2022-12-31 | 13G | Profound Medical Corp. PROF |
James E. Flynn | 0 0.000% |
-1,713,797 (Position Closed) |
Filing History |
| 2023-02-10 10:07 am Sale |
2022-12-31 | 13G | Orchard Therapeutics plc ORTX |
James E. Flynn | 316,171 2.500% |
-378,771 (-54.50%) |
Filing History |
| 2023-02-10 10:06 am Sale |
2022-12-31 | 13G | Organogenesis Holdings Inc. ORGO |
James E. Flynn | 0 0.000% |
-8,456,876 (Position Closed) |
Filing History |